



## Dragoș Mircea Median

**Date of birth:** 15 Jan 1976 | **Nationality:** Romanian | **Gender:** Male | **Phone number:**  
(+40) 744874350 (Mobile) | **Email address:** [dragos.median@gmail.com](mailto:dragos.median@gmail.com) |

**Address:** Filantropia Clinical Hospital, 11 Ion Mihalache Av., 1st Arrond, 011171, Bucharest, Romania (Work)

**Address:** 65 Teleajen St., 2nd Arrond, 4th Floor, 14th Apart., 021468, Bucharest, Romania (Home)

### WORK EXPERIENCE

JUL 2012 – CURRENT Bucharest, Romania

#### CONSULTANT IN MEDICAL ONCOLOGY FILANTROPIA CLINICAL HOSPITAL

- diagnosis, treatment and follow-up of patients with breast cancer or gynecological cancers
- lead the institutional multidisciplinary tumor board
- coordinate as PI the oncology clinical trials involving the institution
- coordinate the institution clinical research in oncology
- manage the institutional budget for oncology program
- supervise the fellows in oncology from institution
- coordinate the medical activity of the department

**Address** Day hospitalization - Medical oncology, 11 Ion Mihalache Av., 1st Arrond, 011171, Bucharest, Romania

JUL 2007 – JUN 2012 Bucharest, Romania

#### SPECIALIST IN MEDICAL ONCOLOGY FILANTROPIA CLINICAL HOSPITAL

- diagnosis, treatment and follow-up of patients with breast cancer or gynecological cancers
- participate to the institutional multidisciplinary tumor board
- work as sub-investigators in the oncology clinical trials involving the institution
- co-manage the institutional budget for oncology program
- coordinate the medical activity of the department

DEC 2003 – JUN 2007 Bucharest, Romania

#### FELLOW IN MEDICAL ONCOLOGY "PROF.DR. ALEXANDRU TRESTIOREANU" INSTITUTE OF ONCOLOGY

- training in Medical oncology (42 months)
  - supervised activity in diagnosis, treatment and follow-up of patients with different neoplasms (mainly breast, lung, colorectal, ovarian, prostate and testicular)
  - involved in clinical research
  - work as study coordinator and sub-investigators in the oncology clinical trials involving the institution
- training in Nuclear medicine (one month)
  - learn the principle of nuclear medicine
  - involved in the bone scan assessment of cancer patients
  - supervised care of patient with thyroid cancer

**Address** 252 Fundeni Road, 2nd Arrond., 022328, Bucharest, Romania

JAN 2002 – NOV 2003 Bucharest, Romania

#### FELLOW IN MEDICAL ONCOLOGY COLTEA HOSPITAL

- training in Internal medicine (9 months)
- training in Cardiology (3 months)
- training in Hematology (3 months)
- training in Radiology and Medical imaging (3 months)

- training in Radiotherapy (3 months)
- training in Pathology (2 months)

**Address** 1 I.C.Bratianu Av., 3rd Arrond, 030171, Bucharest, Romania

JAN 2001 – DEC 2001 Botoşani, Romania

**TRAINEE DOCTOR MAVROMATI COUNTY HOSPITAL**

---

- supervised medical care of patients with different pathologies

## ● **PROFESSIONAL COMMITTEE**

---

2008 – 2016

**Member of the expert's committee of national health insurance house for active monitoring of oncologic specific therapies**

---

2010 – 2016

**Member of the expert's committee of national health insurance house for national program of oncology**

---

## ● **EDUCATION AND TRAINING**

---

27 NOV 2024 – 28 NOV 2024 Lisbon, Portugal

**OPTIMAL MANAGEMENT OF TRIPLE NEGATIVE BREAST CANCER** Champalimaud Breast Cancer

---

Chair: Fatima Cardoso

**Website** [https://fchampalimaud.org/clinical\\_areas/breast](https://fchampalimaud.org/clinical_areas/breast) | **Field of study** Breast cancer

1 SEP 2022 – 2 SEP 2022 on-line

**CLINICAL OBSERVATIONAL PROGRAM: ADVANCED AND EARLY TNBC** Vienna University of Medicine

---

Chairs: Rupert Bartsch, Christian Singer

**Website** <https://www.meduniwien.ac.at/web/en/> | **Field of study** Breast cancer

AUG 2021 on-line

**EXPERT INSIGHTS: INTRINSIC SUBTYPES** University of Barcelona

---

Chair: Aleix Prat

**Website** <https://www.ub.edu/portal/web/medicine-health-sciences> | **Field of study** Breast cancer

20 APR 2018 – 21 APR 2018 Vienna, Austria

**ELEVATE2 - ADVANCING SCIENCE IN HR+/HER2- MBC**

---

Chairs: Michael Grant, Peter Schmid

**Field of study** Breast cancer

**ADVANCING SCIENCE IN HR+/HER2- METASTATIC BREAST CANCER**

---

28 SEP 2017 – 29 SEP 2017 Brussels, Belgium

**INTERNATIONAL BREAST CANCER ACADEMY - BRIDGING RESEARCH AND CLINICAL PRACTICE IN THE ADVANCED CARE SETTING** Institut Jules Bordet

---

Chairs: Ahmad Awada, Véronique Diéras

**Website** <https://www.bordet.be> | **Field of study** Breast cancer

30 MAR 2017 – 31 MAR 2017 Paris, France

**INTERNATIONAL BREAST CANCER ACADEMY - BRIDGING RESEARCH AND CLINICAL PRACTICE IN THE ADVANCED CARE SETTING** Institut Curie

---

Chairs: Ahmad Awada, Véronique Diéras, Javier Cortés

**Website** <https://institut-curie.org> | **Field of study** Breast cancer

2 OCT 2015 Bucharest, Romania

**EFICIENTA HORMONOTERAPIEI IN CANCERUL MAMAR - DE LA STUDII CLINICE LA PRACTICA DE ZI CU ZI**  
Romanian Breast Cancer Group

---

21 FEB 2013 – 22 FEB 2013 Brussels, Belgium

**CURRENT MANAGEMENT OF BREAST CANCER** Institut Jules Bordet

---

Chair: Martine J. Piccart-Gebhart

**Website** <https://www.bordet.be> | **Field of study** Breast cancer

Budapest, Hungary

**SKELETAL CARE ACADEMY** CECOG

---

Chair: Thomas Brodowicz

**Website** <https://www.cecog.org>

2 APR 2011 – 7 APR 2011 Ermatingen, Switzerland

**10TH ESO-ESMO MATERCLASS IN CLINICAL ONCOLOGY** ESO

---

**Website** <https://www.eso.net>

4 MAR 2011 – 5 MAR 2011 Munich, Germany

**10TH ANNUAL COURSE ON ANEMIA, NEUTROPENIA AND THROMBOCYTOPENIA AND CANCER** ESMO, EORTC

---

Chair: Matti Aapro

**Website** [www.esmo.org](http://www.esmo.org)

18 NOV 2010 Bucuresti, Romania

**CANCERUL DE SAN ERBB2+, PREZENT SI PERSPECTIVE** ESO

---

Chair: Alexandru Eniu

**Website** [www.eso.net](http://www.eso.net) | **Field of study** Breast cancer

10 OCT 2008 – 11 OCT 2008 Bucharest, Romania

**ESMO-SIOG COURSE** ESMO, SIOG

---

Chair: Rolf A. Stahel

**Website** [www.esmo.org](http://www.esmo.org)

10 MAY 2007 – 11 MAY 2007 Bucharest, Romania

**PALLIATIVE CARE AND SUPPORTIVE CARE IN MEDICAL ONCOLOGY** ESMO

---

Chair: Rolf A. Stahel

**Website** [www.esmo.org](http://www.esmo.org)

19 APR 2007 – 21 APR 2007 Bucharest, Romania

**MOLECULAR TARGETED THERAPY IN ONCOLOGY: HOPES, FACTS AND FURTHER PROMISES ESMO**

---

Chair: Rolf A.Stahel

**Website** [www.esmo.org](http://www.esmo.org)

24 FEB 2007 – 2 MAR 2007 St.Julians, Malta

**6TH MASTERCLASS IN CLINICAL ONCOLOGY ESO**

---

**Website** [www.eso.net](http://www.eso.net)

14 FEB 2007 – 16 FEB 2007 Barcelona, Spain

**ESMO TRU VISIT - AN INTRODUCTION TO TRANSLATIONAL RESEARCH IN ONCOLOGY** Vall d'Hebron  
Barcelona Hospital

---

Chair: José Baselga

**Website** <https://www.vallhebron.com/en> | **Field of study** Breast cancer

23 SEP 2005 – 25 SEP 2005 Bucharest, Romania

**ESMO 5X5X5 EDUCATIONAL PROGRAMME - GASTROINTESTINAL TUMORS ESMO**

---

Chair: H.J.Schmoll

**Website** [www.esmo.org](http://www.esmo.org) | **Field of study** Gastrointestinal tumors

9 SEP 2005 Craiova, Romania

**ACTUALITATI IN DIAGNOSTICUL SI TRATAMENTUL CANCERULUI GLANDEI MAMARE** UMF Craiova

---

Chair: Florinel Bădulescu

**Website** <https://www.umfcv.ro> | **Field of study** Breast cancer

24 JUN 2005 – 25 JUN 2005 Bucuresti, Romania

**UPDATE IN MANAGEMENT OF THE SOLID TUMORS ESMO, SIOG**

---

Chair: Dirk Schrijvers

**Website** [www.esmo.org](http://www.esmo.org)

30 SEP 2004 – 2 OCT 2004 Bucharest, Romania

**ESMO 5X5X5 EDUCATIONAL PROGRAMME - HEAD AND NECK THORACIC TUMOURS ESMO**

---

Chair: Heine H.Hansen

**Website** [www.esmo.org](http://www.esmo.org) | **Field of study** Head and Neck Cancers

2 APR 2004 – 4 APR 2004 Bucharest, Romania

**FUNDAMENTALS IN MEDICAL ONCOLOGY ESMO**

---

Chair: Dirk Schrijvers

**Website** [www.esmo.org](http://www.esmo.org)

1 OCT 1994 – 31 JUL 2000 Iasi, Romania

**PHYSICIAN, MD** University of Medicine and Pharmacy "Gr.T.Popa"

---

**Website** [www.umfiasi.ro](http://www.umfiasi.ro) | **Level in EQF** EQF level 7

15 SEP 1990 – 30 JUN 1994 Botosani, Romania

**HIGH SCHOOL DIPLOMA** "Mihai Eminescu" High school

---

**Website** [www.lme.ro](http://www.lme.ro)

## ● NETWORKS AND MEMBERSHIPS

---

2002 – CURRENT

### **National Society of Medical Oncology from Romania (SNOMR)**

---

- member of the board
- responsible for the organization and coordination of working groups

2004 – CURRENT

### **European Society of Medical Oncology (ESMO)**

---

2004 – 2010

### **Balkan Union of Oncology**

---

2006 – CURRENT

### **American Society of Clinical Oncology (ASCO)**

---

## ● HONOURS AND AWARDS

---

18 NOV 2006

### **AIOM Young Investigator Award 2006 – AIOM**

---

## ● PUBLICATIONS

---

2022

### **Cancerul mamar - actualități 2022**

---

**Book chapter** in "Terapii moderne în cancer 2022"

Coordinator: Prof. Dr. Șerban Negru

București: Ed. Viața Medicală: Medichub Media, 2022

ISBN 978-606-95567-0-2

ISBN 978-606-95565-1-1

Dragoș Mircea Median, George Iancu, Andrei Ioan Corha, Simona Ruxandra Volovăț

2021

### **Cancerul mamar - actualități 2021**

---

**Book chapter** in "Terapii moderne în cancer 2021"

Coordinator: Prof. Dr. Lucian Miron

București : Ed. Viața medicală : Medichub Media, 2021

ISBN 978-606-95339-1-8

ISBN 978-606-95260-2-6

Dragoș Mircea Median, George Iancu, Andrei Ioan Corha

2017

### **Cancerul de sân în sarcină**

---

**Book chapter** in "Afecțiuni medicale în sarcină"

Coordinator: Anca Maria Panaitescu

Co-coordinator: Prof. Dr. Gheorghe Peltecu

București, Ed. Academiei Române, 2017

ISBN 978-973-27-2757-7

Anca Maria Panaitescu, Mihaela Demetrian, Dragoș Median, Gheorghe Peltecu

2014

### **Sarcina și cancerul: de la diagnostic la tratamente**

---

**Book**

București; Ed. Medicală, 2014;

ISBN 978-973-39-0780-0

Anca Angela Simionescu, Dragoș Median

2007

## **Patologia ginecologică malignă – Cancerul ovarian epitelial**

---

**Book chapter** in "Tratat de chirurgie, vol V. A, Ginecologie"

Coordinator: Prof. dr. Irinel Popescu

București; Editura Academiei Române, 2007;

ISBN 978-973-27-1580-2

ISBN 978-973-27-1658-8

Gheorghe Peltecu, Mioara Ionescu, Viorica Nagy, Dan Jinga, Dragoș Median

2005

## **Actualități privind tratamentul sistemic și stadializarea cancerului mamar**

---

### **Book**

Satu-Mare, Ed. Daya, 2005

ISBN 973-7756-04-5

Mircea Dediu, Rodica Anghel, Dumitru Nuțu, Șerban Donea, Emilian Bușilă, Dragoș Median

2019

## **Ghidul Societății de Obstetrică și Ginecologie din România - Cancerul de col uterin**

---

### **Guidelines**

Coordinator: Prof.Dr. Gheorghe Peltecu

Societatea de Obstetrică și Ginecologie din România;

Colegiul Medicilor din România, 2019

Gheorghe Peltecu, Eugen Căne, Ruxandra Cigăran, Nicolae Gică, George Iancu, Mioara Ionescu, Dragoș Mircea Median, Loredana Tuinea, Ștefănel Vlad

**Link** <https://sogr.ro/wp-content/uploads/2019/06/27.-Cancerul-de-col-uterin.pdf>

2019

## **Ghidul Societății de Obstetrică și Ginecologie din România - Cancerul mamar**

---

### **Guidelines**

Coordinator: Prof.Dr. Gheorghe Peltecu

Societatea de Obstetrică și Ginecologie din România;

Colegiul Medicilor din România, 2019

Gheorghe Peltecu, Dragoș Mircea Median, Ștefănel Vlad, Loredana Tuinea, George Iancu, Nicolae Gică, Florina Nedelea, Ruxandra Cigăran, Raluca Chirculescu, Mihai Lesaru, Laura Mustață, Alexandra Tenovici, Daniela Ilie, Elena Cocîrță, Andrei Corha

**Link** <https://sogr.ro/wp-content/uploads/2019/06/30.-Cancerul-mamar.pdf>

2024

## **The importance of resuming hormone treatment after pregnancy. Case presentation: invasive ductal carcinoma RH+, HER2Neu+**

---

### **Paper**

Revista Societății Române de Obstetrică și Ginecologie • Vol. LXXII • Nr. 3 • iulie-septembrie 2024 (144-148)

Ștefania-Loredana Negoianu, Dominic Iliescu, Dragoș Median, Loredana Tuinea

2024

## **Digging in real-word electronic database for assessing CDK 4/6 inhibitors adherence in breast cancer patients from Romania**

---

### **Paper**

Front. Pharmacol. 15:1345482.

doi: 10.3389/fphar.2024.1345482

Turcu-Stiolica Adina, Udristoiu Ion, Subtirelu Mihaela Simona, Gheorman Victor, Aldea Madalina, Dumitrescu Elena, Volovat Simona Ruxandra, Median Dragoș Mircea, Lungulescu Cristian Virgil

**Link** <https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1345482/full>

2023

## **Second primary breast cancer during PARP inhibitor treatment of somatic BRCA mutant ovarian cancer – a case report**

---

### **Paper**

Oncolog-Hematolog.ro  
JOURNAL FOR CONTINUING MEDICAL EDUCATION  
Year XVII • No. 63 (2) 2023 • DOI: 10.26416/OnHe.63.2.2023

Dragoş Mircea Median, Simona Coniac, Andreea-Iuliana Miron

2021

## **COVID-19 Pandemic Impact on Cord Blood Collection for Stem Cell Use and Actual Perspectives**

---

### **Paper**

Maedica (Bucur). 2021 Jun;16(2):184-188.  
doi: 10.26574/maedica.2021.16.2.189

Daia Mihai Tiberiu , Median Dragoş, Buinoiu Natalia , Ciocarlan Maria, Iancu George, Panaitescu Anca Maria, Peltecu Gheorghe, Streinu-Cercel Adrian

**Link** <https://pmc.ncbi.nlm.nih.gov/articles/PMC8450644/>

2021

## **Sentinel Lymph Node Biopsy in Breast Cancer. Principle, Difficulties and Pitfalls**

---

### **Paper**

Chirurgia (Bucur). 2021 Oct;116(5):533-541.  
doi: 10.21614/chirurgia.116.5.533.  
PMID: 34749849.

George Iancu, Laura Mihaela Mustață, Ruxandra Cigăran, Nicolae Gică, Radu Botezatu, Dragoş Median, Anca Maria Panaitescu, Gheorghe Peltecu

2021

## **Hepatitis B Virus Reactivation in Oncological Patients who Underwent Chemotherapy. Filantropia Clinical Hospital Five Years' Experience**

---

### **Paper**

MAEDICA – a Journal of Clinical Medicine  
<https://doi.org/10.26574/maedica.2021.16.2.184>

Mihail Tiberiu DAIA, Dragoş MEDIAN, Natalia Florina BUINOIU, Maria CIOCARLAN, George IANCU, Anca Maria PANAITESCU, Gheorghe PELTECU, Adrian STREINU-CERCEL

**Link** [https://www.maedica.ro/articles/2021/2/2021\\_16\(19\)\\_No2\\_pg184-188.pdf](https://www.maedica.ro/articles/2021/2/2021_16(19)_No2_pg184-188.pdf)

2020

## **Real-World Data Analysis of Pregnancy-Associated Breast Cancer at a Tertiary-Level Hospital in Romania**

---

### **Paper**

Medicina (Kaunas). 2020 Oct 6;56(10):522.  
doi: 10.3390/medicina56100522.  
PMID: 33036248;  
PMCID: PMC7600631.

Anca Angel Simionescu, A.Horobet, L.Belascu, Dragoş Mircea Median

**Link** <https://www.mdpi.com/1648-9144/56/10/522>

2018

## **Hepatitis B Virus Reactivation During Chemotherapy For Breast Cancer**

---

### **Paper**

Obstetrica si Ginecologia LXVI (2018) 15-19

Mihai Tiberiu Daia, Dragos Median, Gheorghe Peltecu, Adrian Streinu-Cercel, Anca Maria Panaitescu, Radu Botezatu, Nicola Gică, George Iancu

2017

### **Advanced metastatic breast cancer in pregnancy: the imperative of physical breast examination in pregnancy**

---

#### **Paper**

Rom J Morphol Embryol 2017, 58(2):645-650

Anca Angel Simionescu, C.V.Georgescu, M.C.Ghilusi, S.I.Stoica, Mircea Dragoş Median

2015

### **Chemotherapy For Breast Cancer During Pregnancy And Postpartum: A Retrospective Descriptive Study**

---

#### **Paper**

Farmacia, 2015, Vol 63,3

Anca Angela Simionescu, Dragoş Median

2014

### **Zolendronic acid, a prophylactic and an antiosteoporotic treatment in estrogen positive breast cancer**

---

#### **Paper**

Current Health Sciences Journal 2014, vol.40, suppl.5, pg 99-108

Rosca Roxana, Oros S., Paun D.L., Dumitrascu A., Hortopan D., Stoiceanu M., Vladioiu S., Danciulescu Miulescu R., Median Dragoş, Dumitrache C.

### **Impact of adjuvant chemotherapy in stage IB non-small-cell lung cancer: an analysis of 112 consecutively treated patients.**

---

#### **Paper**

J BUON. 2012 Apr-Jun;17(2):317-22.

Dediu Mircea, Ion Oana, Ion Radu, Alexandru Aurelia, Median Dragoş, Gal Cristi, Horvat Theodor, Motas Camelia, Motas Nicolae

2009

### **Controversies around the use of monoclonal antibodies in the treatment of advanced non-small cell lung cancer.**

---

#### **Paper**

J BUON. 2009 Sep;14 Suppl 1:S159-64.

Dediu Mircea, Ion Oana, Ion Radu, Gal Cristi, Median Dragoş, Gongu Mircea

### **Adjuvant therapy with aromatase inhibitors in postmenopausal, estrogen receptor- positive breast cancer patients: upfront or sequential?**

---

#### **Paper**

J BUON. 2009 Jul-Sep;14(3):375-9.

Dediu Mircea, Median Dragoş, Alexandru Aurelia, Vremes Georgeta, Gal Cristi, Gongu Mircea

2009

### **The favorable prognostic significance of atelectasis in patients with advanced non-small cell lung cancer: results of a prospective observational study.**

---

#### **Paper**

Lung Cancer. 2009 Feb;63(2):271-6.

doi: 10.1016/j.lungcan.2008.05.007. Epub 2008 Jun 20.

Dediu Mircea, Crisan Emilia, Radut Maria, Tarlea Alin, Median Dragoş, Alexandru Aurelia, Vremes Georgeta, Gal Cristi

2007

## **Tyrosine kinase inhibitors in non-small cell lung and pancreatic cancer: the emerging role of erlotinib.**

---

### **Paper**

J BUON. 2007 Sep;12 Suppl 1:S137-49.

Dediu Mircea, Median Dragoş, Alexandru Aurelia, Vremes Georgeta, Gal Cristi

2006

## **Compliance with adjuvant chemotherapy in non-small lung cancer. The experience of a single institution evaluating a cohort of 356 patients**

---

### **Paper**

Journal of BUON, 11:425-433, 2006 , Oct-Dec 2006

Mircea Dediu, Aurelia Alexandru, Dragoş Median, Rodica Anghel, Alin Țârlea, Polixenia Iorga, Mirela Movanu

2005

## **Anthracycline pre-treated patients: who is who in the chemotherapy choice of relapsed breast cancer?**

---

### **Paper**

Journal of BUON, 2005 Jul-Sep;10(3):323-8

Mircea Dediu, Aurelia Alexandru, Dragoş Median

2005

## **Chemotherapy for resectable non-small cell lung cancer. It's time for a change in the current paradigm**

---

### **Paper**

A Special edition of Journal of BUON 2005, Sept; 61- 88.

ISSN 1107-0625.

First Educational Course of BSO Volos, Greece, 16-17 Sep. 2005

Mircea Dediu, Aurelia Alexandru, Dragoş Median, Georgeta Vremes

2005

## **New trends in adjuvant chemotherapy for non-small-cell lung cancer**

---

### **Paper**

Pneumologia. 2005 Apr-Jun;54(2):89-93.

Dediu Mircea, Alexandru Aurelia, Median Dragoş, Vremeş Georgeta

2023

## **Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC)**

---

### **Abstract**

Journal of Clinical Oncology

Volume 41, Number 16\_suppl

[https://doi.org/10.1200/JCO.2023.41.16\\_suppl.501](https://doi.org/10.1200/JCO.2023.41.16_suppl.501)

Erika P. Hamilton, J.H. Kim, N. Eigeliene, D. Mavroudis, Dragos Mircea Median, H. Marconato, S. Shevnia, O. Ozyilkan, J.M. Puig, C. M. Shannon, Maria Munoz, Belén San Antonio, Ran Wei, Joyce O'Shaughnessy, Stephen R. D. Johnston, Valentina Guarneri

**Link** [https://doi.org/10.1200/JCO.2023.41.16\\_suppl.501](https://doi.org/10.1200/JCO.2023.41.16_suppl.501)

2021

## **Characterization of venous thromboembolic events (VTE), elevated aminotransferases (EAT) and interstitial lung disease (ILD) in monarchE**

---

### **Abstract**

Annals of Oncology (2021) 32 (suppl\_2): S37-S47.

M. Toi, Nadia Harbeck, J.M. Puig, J. Cruz, J.H. Seo, M. Takahashi, M. Hulstijn, E.A. Twum, A. Regev, B. San Antonio, Dragoş Mircea Median, M. Campone

2020

### **Breast conserving surgery in breast cancer after neoadjuvant chemotherapy – opportunity of radioopaque tumor marking clips**

---

#### **Abstract**

European Journal of Cancer 138, Suppl. 1 (2020) S18–S124  
[https://doi.org/10.1016/S0959-8049\(20\)30618-3](https://doi.org/10.1016/S0959-8049(20)30618-3)

George Iancu, Laura Mustăţă, Loredana Tuinea, Andrei Corha, Beatrice Median, Gheorghe Peltecu, Dragoş Median

**Link** [https://doi.org/10.1016/S0959-8049\(20\)30618-3](https://doi.org/10.1016/S0959-8049(20)30618-3)

2019

### **Prevalence and spectrum of BRCA mutations in patients with platinum-sensitive ovarian cancer from Romania – results of an observational study**

---

#### **Abstract**

Int J Gynecol Cancer: first published as 10.1136/ijgc-2019-ESGO.1033 on 1 November 2019

Dana Lucia Stanculeanu, Dragoş Mircea Median, Cristina Cebotaru, Gabriela Teodorescu, Corina Voinea

2019

### **Tumor infiltrating lymphocytes – marker of therapy response in breast cancer**

---

#### **Abstract**

Int J Gynecol Cancer: first published as 10.1136/ijgc-2019-ESGO.270 on 1 November 2019

George Iancu, Gheorghe Peltecu, Dana Terzea, Dragoş Median

2019

### **What we can and what we may in HER2-positive breast cancer**

---

#### **Abstract**

Oncolog-Hematolog.ro Year XIII • No. 48 (3) 2019 •  
DOI: 10.26416/OnHe.48.3.2019

Dragoş Median

2019

### **Ovarian cancers – looking over the fence**

---

#### **Abstract**

Oncolog-Hematolog.ro Year XIII • No. 48 (3) 2019 •  
DOI: 10.26416/OnHe.48.3.2019

Dragoş Median, George Iancu, Andrei Corha

2018

### **PREvalence of BRCA mutations and correlations with Demographic and clinical characteristics in patients with ovarian, fallopian tube or primary peritoneal cancer in Romania (PREDICT)**

---

#### **Abstract**

Annals of Oncology, Volume 29, Issue suppl\_6, 1 September 2018, mdy314.048,  
<https://doi.org/10.1093/annonc/mdy314.048>

Cristina Cebotaru Dana Lucia Stanculeanu, Dragoş Mircea Median

**Link** <https://doi.org/10.1093/annonc/mdy314.048>

2014

### **Value of molecular therapy in advanced and metastatic cervical cancer**

---

#### **Abstract**

Dragoş Median, George Iancu

2006

---

**Patient outcome following adjuvant chemotherapy (CT) in completely resected stage I-IIIB, non-small cell lung cancer (NSCLC)**

---

**Abstract**

Lung cancer, 2006 ;52 ( Suppl 2) : S20 (abstrO.8), 2006 ISBN 88-7587-250-3, CD ISBN 88-7587-251-1

Mircea Dediu, Teodor Horvat, Rodica Anghel, Alin Țârlea, Aurelia Alexandru, Dragoş Median, C.Nistor, Polixenia Iorga, C.Savu, C.Grozavu

2005

---

**Adjuvant Chemotherapy and patient compliance in non-small cell lung cancer (NSCLC). A multivariate analysis of 356 consecutively treated patients**

---

**Abstract**

Eur J. Cancer 2005;3:337 (abstr #1167)

Mircea Dediu, Aurelia Alexandru, Dragoş Median

2017

---

**Tumora cu celule de granuloasă - prezentare de caz**

---

**Poster**

ginecologia.ro, Anul V, Nr.15 (1/2017)

A. Moldoveanu, Dragoş Median, C. Herghelegiu, D. Oprescu

2014

---

**Chemotherapy for breast cancer during pregnancy: case report series**

---

**Poster**

The Breast - Volume 23, Supplement, November 2014, Pages S21

Dragoş Median, Gheorghe Peltecu, George Iancu, Anca Simionescu, Maria Bari

2012

---

**The prognostic value of MMP-9, MMP-2, TIMP-1 and TIMP-2 in breast cancer after twelve years of initial investigation**

---

**Poster**

Ann Oncol (2012) 23 (suppl 9):ix67–ix72, 2012 (Abstr 146P), Abstract Book of the 37th ESMO Congress Vienna, Austria, 28 September – 2 October 2012

Dan Corneliu Jinga, Alexandru Blidaru, Ileana Condrea, Carmen Ardeleanu, Dragoş Median

2010

---

**Impact of adjuvant chemotherapy in stage IB non-small-cell lung cancer: an analysis of 112 consecutively treated patients.**

---

**Poster**

Journal of Thoracic Oncology • Volume 5, Number 5, Supplement 1, Page S69-70 (175PD) May 2010

Dediu Mircea, Ion Oana, Ion Radu, Alexandru Aurelia, Median Dragoş, Gal Cristi, Gongu Mircea

2007

---

**Prognostic value of atelectasis for locally advanced non-small cell lung cancer (NSCLC)**

---

**Poster**

Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, Page S524, August 2007 - 12th World Conference on Lung Cancer. September 2 - 6, 2007. Seoul, Korea -

Mircea Dediu, Dragoş Median, Rodica Anghel, Cristi Gal, Aurelia Alexandru

2006

## **Atelectasis as a good prognostic factor for advanced non-small cell lung cancer (NSCLC)**

---

### **Poster**

Annals of Oncology 2006, 17 (Suppl 9): ix231 (Abstr 7825P) 31st ESMO Congress, Istanbul, Turkey, 29Sep – 03Oct 2006

Mircea Dediu, Rodica Anghel, Dragoş Median, Aurelia Alexandru, Dumitru Nuţu, Alin Țârlea, Anca Silaghi, Georgeta Vremeş, Cristi Gal, Loredana Nedeluş

2025

## **Chemo-radiation dose intensity for patients with locally advanced non-small cell lung cancer (NSCLC), treated with split course radiation and concurrent vinorelbine (NVB) plus cisplatin(CDDP)**

---

### **Poster**

J Clin Oncol 23 (suppl 16S), Part I of II, pp:700s, (Abstr 7322.), 41-st American Society of Clinical Oncology Annual Meeting -Orlando, Florida, May 2005

Mircea Dediu, Alin Tarlea, Aurelia Alexandru, Dragoş Median, Maria Radut

2004

## **The impact of surgery on the outcome of patients with non-small cell lung cancer (NSCLC) and brain metastasis**

---

### **Poster**

Annals of Oncology 2004, 15 (Suppl 3): iii171 (Abstr 645P), ESMO Congress – Vienna, 29 Oct – 2 Nov 2004

Mirce Dediu, Theodor Horvat, Alin Tarlea, Dragoş Median, Aurelia Alexandru, Geanina Miron

## **CLINICAL TRIALS**

---

2025 – CURRENT

### **Elacestrant versus Standard Endocrine Therapy in Women and Men with Nodepositive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)**

---

Role: PI

Sub-investigators: Loredana Tuinea, Ruxandra Cigaran

Study coordinator: Marian Pasa

Code: STML-ELA-0422 (ELEGANT)

NCT06492616

Sponsor: Stemline Therapeutics, Inc.

CRO: Parexel

2024 – CURRENT

### **A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)**

---

Role: PI

Sub-investigators: Loredana Tuinea, Ruxandra Cigaran

Study coordinator: Marian Pasa

Code:CO44657; pionERA Breast Cancer

NCT06065748

Sponsor: Hoffmann-La Roche

CRO: IQVIA

2024 – CURRENT

### **A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2-Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)**

---

Role: PI

Sub-investigators: Loredana Tuinea, Ruxandra Cigaran

Study coordinator: Marian Pasa

Code: MK-2870-010  
NCT06312176  
Sponsor: Merck Sharp & Dohme LLC  
CRO: MSD

2024 – CURRENT

**An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men with Locally Advanced or Metastatic ER+/HER2– Breast Cancer with an ESR1 Mutation**

---

Role: PI  
Sub-investigators: Loredana Tuinea, Ruxandra Cigaran  
Study coordinator: Marian Pasa

Code:SMX 22-002 (ELAINE 3)  
NCT05696626  
Sponsor: Sermonix Pharmaceuticals Inc.  
CRO: Augustresearch

2024 – CURRENT

**A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833), a Next Generation, Oral Selective Estrogen Receptor Degradar) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease**

---

Role: PI  
Sub-investigators: Loredana Tuinea, Ruxandra Cigaran  
Study coordinator: Marian Pasa

Code: D8535C00001 (CAMBRIA-2)  
NCT05952557  
Sponsor: Astra Zeneca  
CRO: Fortrea

2023 – CURRENT

**Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period**

---

Role: PI  
Sub-investigator: Bogdan Maxim

NCT05135104  
Sponsor: Asociatia Oncohelp - Centrul de Oncologie Oncohelp

2022 – 2024

**Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)**

---

Role: PI  
Sub-investigators: Loredana Tuinea  
Study coordinator: Teodora (Cioroba) Nitescu

Code: D967UC00001  
Sponsor: Astra Zeneca

2023 – CURRENT

**A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors do Express PD-L1**

---

Role: PI  
Sub-investigators: Loredana Tuinea  
Study coordinator: Teodora (Cioroba) Nitescu

Code: GS-US-592-6238 (ASCENT-03)  
NCT05382299  
Sponsor: Gilead  
CRO: ICON

2022 – 2024

---

**Evaluation of the Clinical Performance of the PAXgene Blood ccfDNA Tube in Comparison to the BD Vacutainer K2EDTA Tube Using the theascreen® PIK3CA RGQ PCR Kit**

---

Role: PI  
Sub-investigator: Loredana Tuinea

Code: PAS-18CCF006  
Sponsor: Becton, Dickinson and Company

2022 – CURRENT

---

**"Collection and Processing of Whole Blood Specimens from Breast Cancer Patients for use in the Analytical Studies of the PAXgene Blood ccfDNA Tube US-IVD Project"**

---

Role: PI  
Sub-investigator: Loredana Tuinea

Code: PAS-18CCF007  
Sponsor: Becton, Dickinson and Company

2022

---

**A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate The Efficacy And Safety Of Adjuvant Atezolizumab Or Placebo And Trastuzumab Emtansine For Her2-Positive Breast Cancer At High Risk Of Recurrence Following Preoperative Therapy**

---

Role: PI  
Sub-investigators: Loredana Tuinea, Ruxandra Cigaran  
Study coordinator: Teodora (Cioroba) Nitescu

Code: WO42633 (Astefania)  
NCT04873362  
Sponsor: Hoffmann-La Roche  
CRO: IQVIA

2022 – CURRENT

---

**A Phase III, Randomized, Open-Label, Multicenter Study Evaluating The Efficacy And Safety Of Adjuvant Giredestrant Compared With Physician's Choice Of Adjuvant Endocrine Monotherapy In Patients With Estrogen Receptor-Positive, Her2-Negative Early Breast Cancer**

---

Role: PI  
Sub-investigators: Loredana Tuinea, Ruxandra Cigaran  
Study coordinator: Teodora (Cioroba) Nitescu

Code: lidERA (GO42784)  
NCT04961996  
Sponsor: Hoffmann-La Roche  
CRO: PPD

2022 – 2024

---

**A Randomized Phase 3 Double-Blinded Study Comparing The Efficacy And Safety Of Niraparib To Placebo In Participants With Either Her2-Negative BRCA-Mutated Or Triple-Negative Breast Cancer With Molecular Disease Based On Presence Of Circulating Tumor DNA After Definitive Therapy (ZEST)**

---

Role: PI  
Sub-investigators: Loredana Tuinea  
Study coordinator: Teodora (Cioroba) Nitescu

Code: GSK3985771 (ZEST)  
NCT02655016  
Sponsor: GSK  
CRO: PPD

2021 – 2024

**A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer**

---

Role: PI  
Sub-investigator: Loredana Tuinea, Andrei Anica, Laura Mustata  
Study coordinator: Anderi Corha

Code: CA2097FL (CheckMate 7FL)  
NCT04109066  
Sponsor: Bristol Myers Squibb  
CRO: BMS

2020 – CURRENT

**A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer**

---

Role: PI  
Sub-investigator: Loredana Tuinea, George Iancu, Laura Mustata  
Study coordinator: Andrei Corha

Code: CLEE011O12301C (TRIO033 / NATALEE)  
NCT03701334  
Sponsor: Novartis  
CRO: HT Research RO

2020 – 2020

**A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy**

---

Role: PI  
Sub-investigator: Loredana Tuinea  
Study coordinator: Andrei Corha

Code: CO-338-087/ GOG-3020/ ENGOT-ov45/NCRI/ATHENA  
NCT03522246  
Sponsor: Clovis Oncology, Inc.  
CRO: Rotrial

2017 – 2018

**PREvalence of BRCA mutations and correlations with Demographic and clinical characteristics in patients with ovarian, fallopian tube or primary peritoneal cancer in Romania (PREDICT)**

---

Role: PI  
Code: D133FR00135  
Sponsor: Astra Zeneca  
CRO: Medinteractiv

2018 – 2023

**A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer (IMpassion030)**

---

Role: PI  
Sub-investigator: Loredana Tuinea

Study coordinator: Andrei Corha

Code:BIG 16-05/AFT-27/WO39391  
NCT03498716  
Sponsor: Hoffmann-La Roche  
CRO: PRA Health sciences

2018 – 2024

**A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA)**

---

Role: PI  
Sub-investigator: Loredana Tuinea  
Study coordinator: Andrei Corha

Code: MO39146  
NCT02913456  
Sponsor: Hoffmann-La Roche  
CRO:IQVIA

2017 – CURRENT

**A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer**

---

Role: PI  
Sub-investigators: Gheorghe Peltecu, Loredana Tuinea, George Iancu  
Study coordinator: Andrei Corha

Code: I3Y-MC-JPCF (monarchE)  
NCT03155997  
Sponsor: Eli Lilly and Company  
CRO: IQVIA

2016 – 2018

**A phase III randomised double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer wich progressed on or after aromatase inhibitor (AI) treatment**

---

Role: PI  
Sub-investigators: Gheorghe Peltecu, George Iancu, Mircea Gongu

Code:SOLAR-1  
NCT02437318  
Sponsor: Novartis  
CRO: Novartis

2016 – 2017

**A Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) vs. Pegylated Liposomal Doxorubicin or Topotecan in Patients with Platinum-resistant Ovarian Cancer (CORAIL Trial)**

---

Role: PI  
Sub-investigators: Mircea Gongu, George Iancu, Gheorghe Peltecu

Code: CORAIL  
NCT02421588  
Sponsor: PharmaMar  
CRO: INC Research

2015 – 2016

**A Randomized Open-label Phase II Study of Letrozole Plus Afatinib (BIBW2992) Versus Letrozole Alone in First Line Treatment of Advanced ER+, HER2- Post-menopausal Breast Cancer With Low ER Expression**

---

Role: PI  
Sub-investigators: Mircea Gongu, George Iancu

Code: TRIO-020  
NCT02115048  
Sponsor: Translational Research in Oncology  
CRO: HT Research RO

2014 – 2016

**A Phase III Randomised, Double-Blind, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB3 (proposed trastuzumab biosimilar) and Herceptin® in Women with Newly Diagnosed HER2 Positive Early or Locally Advanced Breast Cancer in Neoadjuvant Setting**

---

Role: PI  
Sub-investigators: Gheorghe Peltecu, George Iancu

Code: SB3-G31-BC  
NCT02149524  
Sponsor: Samsung Bioepis Co., Ltd.  
CRO: Quintiles

2014 – 2017

**A Multicenter, Double-Blind, Randomized, Parallel-Group, Phase III Study Of The Efficacy And Safety Of Hercules Plus Taxane Versus Herceptin® Plus Taxane As First Line Therapy In Patients With Her2-Positive Metastatic Breast Cancer**

---

Role: SI  
Principal investigator: Gheorghe Peltecu  
Sub-investigators: Dragoş Median, Nicolae Gica

Code:MYL-Her3001  
Sponsor: MYLAN GmbH  
CRO: INC Research

2014 – 2015

**A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.**

---

Role: PI  
Sub-investigators: Gheorghe Peltecu, George Iancu

Code: OlympiAD  
NCT02000622  
Sponsor: Astra Zeneca  
CRO: Astra Zeneca

2013 – 2016

**Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy**

---

Role: PI  
Sub-investigator: Ana Maria Radu  
Code: Amgen 20120214  
NCT02178475  
Sponsor: Amgen  
CRO: Quintiles

2010 – 2013

**Multicenter, Single-arm, Observational Study of Mean Duration of Trastuzumab Treatment for Early and Metastatic Breast Cancer in Romanian Population (HERODOT)**

---

Role: PI

Code: ML25235  
NCT01187381  
Sponsor: Hoffmann-La Roche  
CRO: Hoffmann-La Roche

2010 – 2011

---

**An Open-Label, Single-Arm, Multicenter Phase 2 Study of E7080 in Subjects with Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy**

---

Role: SI  
Principal investigator: Gheorghe Peltecu  
Sub-investigators: Dragos Median, George Iancu

Code: E7080-G000-204  
NCT01111461  
Sponsor: Eisai Inc.  
CRO: PSI

2008 – 2014

---

**Multicentre, Randomised, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Docetaxel Therapy Compared to Placebo Plus Standard Docetaxel Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy**

---

Role: SI  
PI: Mircea Dediu  
Sub-investigator: Dragos Median, Ana Maria Radu

Code:LUME-Lung 1  
NCT00805194  
Sponsor: Boehringer Ingelheim  
CRO: Parexel

2008 – 2014

---

**A Randomized Double-blind Multicenter Phase III Trial of Nintedanib Plus Pemetrexed vs. Pemetrexed/ Placebo in Advanced or Recurrent Non Small Cell Lung Cancer Patients After Failure of First Line Therapy**

---

Role: SI  
PI: Mircea Dediu  
Sub-investigator: Dragos Median, Ana Maria Radu

Code:LUME-Lung 2  
NCT00806819  
Sponsor: Boehringer Ingelheim  
CRO: Parexel

2008 – 2009

---

**A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer**

---

Role: SI  
PI: Mircea Dediu  
Sub-investigator: Dragos Median, Mircea Gongu

Code: 3144A2-3003-WW  
NCT00777101  
Sponsor: Puma Biotechnology, Inc.  
CRO: Wyeth

2007 – 2014

---

**A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease**

---

Role: SI  
PI: Mircea Dediu  
Sub-investigator: Dragos Median

Code: EMR 63325-001  
NCT00409188  
Sponsor: EMD Serono  
CRO: PRA Intl

2007 – 2012

**An Open-label, Randomized, Controlled Phase-II Trial Evaluating the Efficacy and Safety of EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients**

---

Role: SI  
PI: Mircea Dediu  
Sub-investigator: Dragos Median

Code: CT 4002  
NCT00448305  
Sponsor: MediGene  
CRO: pharmanet

2007 – 2009

**Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study: A Randomised, Multicenter Open-label Phase III Study of Neoadjuvant Lapatinib, Trastuzumab and Their Combination Plus Paclitaxel in Women With HER2/ErbB2 Positive Primary Breast Cancer**

---

Role: SI  
PI: Mircea Dediu  
Sub-investigator: Dragos Median, Aurelia Alexandru

Code: IBCSG 37-07/BIG 1-06/ NeoALTTO  
NCT00553358  
Sponsor: GSK  
CRO: GSK

2007 – 2020

**A Randomised, Multi-centre, Open-label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients With HER2/ErbB2 Positive Primary Breast Cancer**

---

Role: SI  
PI: Mircea Dediu  
Sub-investigator: Dragos Median, Aurelia Alexandru

Code: BIG 2-06/N063D/ ALTTO  
NCT00490139  
Sponsor: GSK  
CRO: GSK

2006 – 2009

**A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors (RADIANT)**

---

Role: SI  
PI: Mircea Dediu  
Sub-investigator: Dragos Median, Aurelia Alexandru

Code: RADIANT OSI-774-302  
NCT00373425  
Sponsor: OSI Pharmaceuticals  
CRO: Covance

2006 – 2009

**A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes**

---

Role: SI  
PI: Mircea Dediu  
Sub-investigator: Dragos Median, Aurelia Alexandru

Code: E7389-G000-301  
NCT00337103  
Sponsor: Eisai Inc.  
CRO: PRA Intl

2005 – 2009

**Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients**

---

Role: SI  
PI: Mircea Dediu  
Sub-investigator: Dragos Median, Cristi Gal

Code: IROF-018  
NCT00124566  
Sponsor: Eisai Inc.  
CRO: PSI

2004 – 2005

**Safety and Efficacy of XM 02 in patients with small cell or non small cell lung cancer receiving platinum-based chemotherapy. Multinational, multicentre, randomised, controlled study**

---

Role: SI  
PI: Mircea Dediu  
Sub-investigator: Dragos Median, Anca Silaghi

Code: XM02-03-INT  
Sponsor: BioGeneriX  
CRO: Parexel

● **CONFERENCES AND SEMINARS**

---

2020 – 2024 Poiana Braşov, România

**National Congress of National Society of Medical Oncology from Romania**

---

Organiser and coordinator of Breast cancer sessions in National Congress since 2020

● **LANGUAGE SKILLS**

---

Mother tongue(s): **ROMANIAN**

Other language(s):

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken production	Spoken interaction	
<b>ENGLISH</b>	C1	C1	B1	B1	B1
<b>FRENCH</b>	B1	B1	A2	A2	B1

---

Levels: A1 and A2: Basic user; B1 and B2: Independent user; C1 and C2: Proficient user

- **HOBBIES AND INTERESTS**

---

Squash

---

- **DIGITAL SKILLS**

---

Microsoft Office ( Word , Excel and Power Point ) | Graphic Design (Photoshop, Illustrator, CorelDraw)

- **DRIVING LICENCE**

---

Driving Licence: B